An Ottawa-based firm has been tapped by the federal government for a three-month pilot project designed to look for warning signs for suicide before tragedy strikes.
It’s been a big year in healthcare technology. Healthcare Analytics News™ reached out to experts across our 8 coverage areas to determine which companies, people, and projects made the biggest waves. The winners of 2017 ushered in advances that have turned heads, resulted in measurable improvements, and given reason to believe that this high-speed sector is not built on hype alone.
Digital health made big strides in 2017. With better provider workflows and more integrated core healthcare platforms, healthcare is on the brink of a disruption. As we move into 2018 and the next wave of innovation, here is a look back on the biggest stories that moved the needle in digital health this year.
More women - especially younger women - are testing positive for marijuana use during pregnancy in Northern California, according to a new study. The research letter, published in the Journal of the American Medical Association, analysed the results of urine tests administered during standard prenatal care of 280,000 women enrolled in the Kaiser Permanente Northern California health-care system.
New research has identified a mechanism in the body that appears to act as a kind of internal bathroom scale, registering body weight and telling the brain to reduce or increase food intake as necessary.
A University of Hawai'i Cancer Center researcher has identified how some cancer cells are made to move during metastasis. The research provides a better understanding of how cancer spreads and may create new opportunities for cancer drug development.
How the brain is able to store memories over long periods of time has been a persistent mystery to neuroscientists. In a new study, researchers from the Centre for Integrative Neuroplasticity (CINPLA) at the University of Oslo show that long-lived extracellular matrix molecules called perineuronal nets are essential for distant memories.
New research published in the Journal of Experimental Medicine highlights the pernicious effect of obesity on the long-term health of blood-making stem cells (hematopoietic stem cells).
Analysts and investors think Perjeta’s end-of-the-year indication may not be as lucrative as they once hoped. The FDA green-lighted the drug in tandem with giant Herceptin and chemo for HER2-positive, post-surgery breast cancer patients with a high risk of recurrence. Patients should receive up to 18 cycles of the regimen over the course of one year, according to the indication.
Mallinckrodt, which has landed in hot water multiple times this year, is diversifying beyond its controversial lead seller.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.